Albert Einstein College of Medicine
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1955-01-01
- Employees
- 1.9K
- Market Cap
- -
- Website
- http://einstein.yu.edu
Fremanezumab Shows Dual Efficacy in Treating Both Migraine and Depression in Landmark Trial
• A groundbreaking clinical trial demonstrates that fremanezumab, a CGRP-targeting monoclonal antibody, significantly reduces both migraine frequency and depressive symptoms in patients with comorbid conditions.
• The UNITE study involving 540 patients across 12 countries showed fremanezumab reduced monthly migraine days by 5.1 compared to 2.9 with placebo, with 40% of treated patients achieving at least 50% reduction in migraine days.
• This represents the first placebo-controlled trial to demonstrate significant improvements in both migraine and depression with a single pharmacological intervention, potentially reducing the cumulative burden on patients.
Sleep Disruptions Emerge as Critical Early Indicators of Alzheimer's Disease Risk
• Delayed REM sleep is associated with higher levels of toxic brain proteins linked to Alzheimer's disease, with late-onset REM showing 16% more amyloid and 29% more tau protein compared to early-onset REM.
• Excessive daytime sleepiness and lack of enthusiasm increase the risk of developing motoric cognitive risk syndrome—a pre-dementia condition—by more than three times compared to those without these sleep issues.
• Researchers suggest that screening for and treating sleep disorders may potentially help prevent cognitive decline, highlighting the importance of good sleep hygiene for brain health.
FDA Approves Axsome's Symbravo (Meloxicam and Rizatriptan) for Acute Migraine Treatment
• The FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults, offering a novel multi-mechanistic approach.
• Clinical trials demonstrated that Symbravo can rapidly eliminate migraine pain and allow patients to return to normal functioning with a single dose.
• Studies showed a statistically significant percentage of patients achieved pain freedom and were free from their most bothersome symptom within two hours of dosing versus placebo.
• Axsome Therapeutics anticipates Symbravo will be commercially available in the U.S. in approximately four months, providing a new option for migraine sufferers.
Montefiore Einstein Cancer Center Secures Prestigious Three-Year CoC Accreditation, Highlighting Excellence in Research and Care
• Montefiore Einstein Comprehensive Cancer Center (MECCC) has earned Three-Year Accreditation from the Commission on Cancer, maintaining its position among top U.S. cancer centers.
• The center demonstrates exceptional commitment to research with over 320 active clinical trials and 80% participation from historically underrepresented groups, compared to 8% nationwide.
• MECCC's innovative programs, including AI-driven lung cancer screening, have contributed to a 12% reduction in stage 4 lung cancers in the Bronx, while maintaining high standards in surgical care and nursing education.
Walden Biosciences Strengthens Board with Appointment of Rare Disease Expert Howard Mayer
• Walden Biosciences has appointed Howard Mayer, M.D., former Executive VP of R&D at Ipsen, to its Board of Directors as the company approaches key clinical milestones.
• Dr. Mayer brings extensive experience in clinical development and regulatory affairs, particularly in rare diseases, as Walden prepares for Phase 2 data readout of WAL0921 for glomerular kidney diseases.
• The appointment comes at a strategic time as Walden advances its pipeline, including the progression of WAL0623, a dynamin stabilizer, into clinical trials.
FDA Approves Subcutaneous Opdivo Qvantig for Multiple Solid Tumors
• The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous use, offering a new administration option for various solid tumors.
• The approval was based on the CheckMate-67T trial, demonstrating non-inferior pharmacokinetic exposures and comparable safety to intravenous Opdivo.
• Opdivo Qvantig provides a faster administration time of 3-5 minutes compared to the 30-minute intravenous infusion, enhancing patient convenience.
• This subcutaneous formulation is approved for most previously approved adult solid tumor Opdivo indications, either as monotherapy or in combination with other treatments.
Atogepant Shows Rapid Migraine Relief in Clinical Trials
• Atogepant, a CGRP receptor antagonist, demonstrates rapid reduction in migraine symptoms, potentially starting from the first dose.
• Clinical trials (ADVANCE, ELEVATE, PROGRESS) show atogepant outperforms placebo in reducing migraine days within the first four weeks of treatment.
• Patients on atogepant reported improvements in daily activities and overall quality of life compared to those on placebo.
• The drug's quick onset may encourage treatment adherence, offering hope for those who have discontinued other migraine medications.
ASH 2024: Advances in Prevention and Treatment of Blood Cancers Highlighted
• Daratumumab significantly reduces disease progression risk in high-risk smoldering multiple myeloma patients, offering a new treatment option.
• Acalabrutinib and venetoclax combination demonstrates superior progression-free survival in previously untreated chronic lymphocytic leukemia (CLL) with manageable safety.
• Epcoritamab shows promising response rates in heavily pretreated relapsed/refractory CLL patients, addressing an unmet need.
• Socioeconomic factors significantly impact access to stem cell transplants for acute myeloid leukemia (AML) patients, highlighting disparities in care.
AXS-12 Demonstrates Long-Term Efficacy and Safety in Narcolepsy Phase 3 Trial
• Axsome Therapeutics' AXS-12 (reboxetine) significantly reduced cataplexy attacks compared to placebo in the Phase 3 ENCORE trial, meeting its primary endpoint.
• Long-term treatment with AXS-12 showed sustained improvements in cataplexy, excessive daytime sleepiness, and cognition in patients with narcolepsy.
• The ENCORE trial's results support AXS-12 as a potential novel treatment option for narcolepsy, with a favorable long-term safety and tolerability profile.
• Axsome Therapeutics plans to submit a New Drug Application (NDA) to the FDA for AXS-12 based on the positive Phase 3 results.
NIH's TrialGPT AI Algorithm Streamlines Clinical Trial Matching
• The NIH has developed TrialGPT, an AI algorithm designed to accelerate matching potential volunteers to clinical trials listed on ClinicalTrials.gov.
• TrialGPT identifies relevant clinical trials, explains how individuals meet enrollment criteria, and ranks trials by relevance and eligibility.
• A study showed TrialGPT achieved nearly the same accuracy as clinicians in assessing patient eligibility, while reducing screening time by 40%.
• The AI tool aims to improve clinical trial enrollment, expedite medical research, and reduce barriers to participation for underrepresented populations.
TMB and FGA Biomarkers Predict Anesthetic/Analgesic Immunomodulation Effects on Cancer Survival
• Researchers found that tumor mutational burden (TMB) and fraction genome altered (FGA) can predict how anesthetic and analgesic drugs affect survival in cancer patients.
• Increased TMB and FGA magnified opioid's pro-tumor effects in lung adenocarcinoma, while TMB reduced ketamine's anti-tumor effects.
• In colon adenocarcinoma, increased TMB magnified opioid's anti-tumor effects on recurrence, suggesting a potential precision approach to oncoanalgesia.
• The study identifies potential molecular targets for further exploration, aiming to optimize oncological outcomes through tailored anesthetic/analgesic strategies.
NIH's TrialGPT AI Algorithm Expedites Clinical Trial Matching
• The NIH has developed TrialGPT, an AI algorithm that efficiently matches potential volunteers to clinical trials listed on ClinicalTrials.gov.
• TrialGPT accurately identifies relevant clinical trials for individuals, explaining how they meet enrollment criteria, potentially improving trial enrollment.
• Clinicians using TrialGPT experienced a 40% reduction in patient screening time while maintaining the same level of accuracy in matching patients to trials.
• TrialGPT shows promise in making clinical trial recruitment more effective and reducing barriers to participation, especially for underrepresented populations.
NIH's TrialGPT AI Algorithm Streamlines Clinical Trial Matching
• The NIH has developed TrialGPT, an AI algorithm designed to efficiently match patients to relevant clinical trials listed on ClinicalTrials.gov.
• TrialGPT demonstrated accuracy comparable to human clinicians in assessing eligibility criteria, while reducing screening time by 40% in a pilot study.
• The AI tool aims to reduce barriers to clinical trial enrollment, potentially increasing access for underrepresented populations and improving recruitment.
• Awarded the Director's Challenge Innovation Award, TrialGPT will undergo further evaluation to ensure fairness and real-world performance across diverse populations.
NIH's TrialGPT AI Algorithm Streamlines Clinical Trial Matching for Patients
• Researchers at the NIH developed TrialGPT, an AI algorithm, to efficiently match patients with relevant clinical trials listed on ClinicalTrials.gov.
• TrialGPT analyzes patient data and identifies suitable trials, providing a ranked list with explanations of eligibility criteria, mirroring clinician accuracy.
• A pilot study showed TrialGPT reduced clinician screening time by 40% while maintaining accuracy in matching patients to appropriate trials.
• The AI tool aims to improve clinical trial recruitment, particularly for underrepresented populations, and accelerate medical research advancements.
NIH's TrialGPT AI Expedites Clinical Trial Matching with High Accuracy
• The NIH has developed TrialGPT, an AI algorithm, to streamline matching patients to clinical trials listed on ClinicalTrials.gov.
• TrialGPT accurately identifies relevant clinical trials for eligible patients and explains how they meet enrollment criteria.
• A study showed TrialGPT achieves nearly the same accuracy as clinicians, reducing screening time by 40% in pilot studies.
• The AI tool aims to improve clinical trial enrollment, accelerate medical research, and reduce barriers for underrepresented populations.
NIH's TrialGPT AI Expedites Clinical Trial Matching for Volunteers
• The NIH has developed TrialGPT, an AI algorithm that accelerates matching potential volunteers to clinical trials listed on ClinicalTrials.gov.
• TrialGPT identifies relevant clinical trials for eligible individuals and explains how they meet enrollment criteria, enhancing clinician efficiency.
• A study showed TrialGPT achieves similar accuracy to clinicians, reducing screening time by 40% while maintaining the same level of precision.
• The AI tool aims to improve clinical trial enrollment and reduce participation barriers for underrepresented populations, fostering medical research progress.
FDA Expands Nerivio REN Wearable Approval for Migraine Treatment in Children Aged 8+
• The FDA has expanded the approval of the Nerivio REN wearable device for the acute treatment of migraines in children aged 8 years and older.
• Nerivio REN is the first FDA-cleared, non-drug therapy for acute migraine treatment and the only prescribed preventive migraine treatment for children in this age group.
• Clinical data demonstrated the safety and efficacy of Nerivio REN in children aged 6-11 years, with significant pain and functional disability relief reported.
• The expanded approval offers a new, potentially first-line treatment option for pediatric migraine, addressing the need for well-tolerated and effective therapies.
Neurogene's NGN-401 Gene Therapy Shows Promise in Rett Syndrome Phase 1/2 Trial
• Neurogene's NGN-401 gene therapy demonstrates meaningful gains in skills and developmental milestones in Rett syndrome patients, a neurodevelopmental disease with limited treatment options.
• All participants in the low-dose cohort achieved a rating of "much improved" on the Clinician Global Impression Scale of Improvement (CGI-I) from baseline.
• The gene therapy was well-tolerated, with no signs of MECP2 overexpression toxicity, and most treatment-related adverse events were known potential risks of AAV.
• Neurogene anticipates completing enrollment in the low-dose pediatric cohort by Q4 2024 and has initiated an adolescent/adult cohort to further assess NGN-401's therapeutic potential.
Neurogene's NGN-401 Gene Therapy Shows Promise in Rett Syndrome Trial
• Neurogene's NGN-401 gene therapy demonstrates meaningful skill gains in pediatric Rett syndrome patients, showing improvements in key clinical domains compared to natural disease progression.
• The low-dose cohort of the Phase 1/2 trial exhibited a favorable safety profile, with most treatment-related adverse events being manageable and responsive to steroids.
• All participants in the low-dose cohort achieved a 'much improved' rating on the CGI-I scale and showed improvement in the Rett Syndrome Behavior Questionnaire (RSBQ).
• Neurogene has initiated an adolescent/adult cohort and gained FDA alignment on manufacturing, paving the way for a potential registrational trial for NGN-401.
FDA Approves Johnson & Johnson's Varipulse for Drug-Resistant Paroxysmal Atrial Fibrillation
• The FDA has approved Johnson & Johnson's Varipulse Pulsed Field Ablation (PFA) Platform for drug-resistant paroxysmal atrial fibrillation (AFib).
• The Varipulse platform integrates PFA therapy with the CARTO 3 system, offering real-time imaging and lesion tagging for improved accuracy.
• Clinical data from the admIRE study demonstrated a 100% procedural success rate and a low adverse event rate of 2.9%.
• The approval provides electrophysiologists with a versatile tool that could reduce procedure time and improve patient outcomes in AFib treatment.
© Copyright 2025. All Rights Reserved by MedPath